Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

14.08.2020 | short review | Ausgabe 3/2020 Open Access

memo - Magazine of European Medical Oncology 3/2020

The future of combination therapies in advanced melanoma

memo - Magazine of European Medical Oncology > Ausgabe 3/2020
Christoph Hoeller
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


The combination of Cytotoxic T-Lymphozyte Antigen-4 (CTLA‑4) and Programmed death-1 (PD‑1) antibodies and the combination of BRAF and MEK inhibitors are the current clinical standards for combination immune and targeted therapy for melanoma, respectively. The success of these therapies has stimulated research into novel drug combinations for melanoma, of which a large majority are based on combination with PD‑1 or PD-Ligand 1 (PD-L1) blocking drugs. Thus, the aim is to provide an overview of the most important combination strategies in late stage clinical development and an outlook on drug combinations in early development that might enter larger clinical trials within the next few years.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3/2020

memo - Magazine of European Medical Oncology 3/2020 Zur Ausgabe